{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-052877","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2026-08-05T10:02:36+00:00","discovered_at":"2026-08-05T10:10:04.745011+00:00","generated_at":"2026-08-05T10:10:30.555317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BeOne Medicines Q2 revenue up 30% to $1.7B; raises FY2026 guidance","bullets":["Q2 total revenue $1.71B (+30% YoY); BRUKINSA revenue $1.2B (+31% YoY).","GAAP diluted EPS $2.05; non-GAAP diluted EPS $3.84 (up 71% YoY).","Raised FY2026 revenue guidance to $6.6-6.8B; GAAP op income $1.0-1.1B.","Q2 free cash flow $435M (+98% YoY); six-month total revenue $3.22B (+32% YoY).","CEO cites strong hematology franchise and pipeline momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-052877","json":"https://secwatch.observer/filing/0001628280-26-052877.json","markdown":"https://secwatch.observer/filing/0001628280-26-052877.md","text":"https://secwatch.observer/filing/0001628280-26-052877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/0001628280-26-052877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/bgne-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T10:10:30.555317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}